Literature DB >> 8349379

The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias.

A J Cowley1, A Skene, K Stainer, J R Hampton.   

Abstract

Ninety-five patients with suspected acute myocardial infarction were randomly allocated on admission to hospital on a double blind basis to treatment with lorcainide, a Class 1C anti-arrhythmic drug, or matching placebo. Treatment was continued for 6 weeks. Twenty-four-hour ECG tape recordings were made immediately on admission, on the sixth or seventh day after admission, and again just before the end of the treatment period. Lorcainide was shown to be an effective anti-arrhythmic agent. The study was not designed to evaluate the effect of lorcainide on survival, but there were nine deaths among the 49 patients treated with lorcainide compared with only one in the patients given placebo. These findings are consistent with the results of the First and Second Cardiac Arrhythmia Suppression trials (CAST and CAST-II). This study was carried out in 1980 but was not published at the time: it now provides an interesting example of 'publication bias'.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349379     DOI: 10.1016/0167-5273(93)90279-p

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  16 in total

1.  [Psychiatrists and the pharmaceutical industry].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2003-11       Impact factor: 1.214

2.  Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO.

Authors:  Kay Dickersin; Iain Chalmers
Journal:  J R Soc Med       Date:  2011-12       Impact factor: 5.344

3.  Therapeutic fashion and publication bias: the case of anti-arrhythmic drugs in heart attack.

Authors:  John Hampton
Journal:  J R Soc Med       Date:  2015-10       Impact factor: 5.344

4.  The health of European medical research. Attempts are under way to update EU regulations, with the aim of harmonizing clinical research across the continent.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2011-02       Impact factor: 8.807

Review 5.  Reproducible pharmacokinetics.

Authors:  John P A Ioannidis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-19       Impact factor: 2.745

6.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

Review 7.  Reporting bias in medical research - a narrative review.

Authors:  Natalie McGauran; Beate Wieseler; Julia Kreis; Yvonne-Beatrice Schüler; Heike Kölsch; Thomas Kaiser
Journal:  Trials       Date:  2010-04-13       Impact factor: 2.279

8.  A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.

Authors:  Keith B Hoffman; Mo Dimbil; Nicholas P Tatonetti; Robert F Kyle
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606

9.  Systematic review of the effectiveness of training programs in writing for scholarly publication, journal editing, and manuscript peer review (protocol).

Authors:  James Galipeau; David Moher; Becky Skidmore; Craig Campbell; Paul Hendry; D William Cameron; Paul C Hébert; Anita Palepu
Journal:  Syst Rev       Date:  2013-06-17

10.  Defining publication bias: protocol for a systematic review of highly cited articles and proposal for a new framework.

Authors:  Katharina Felicitas Müller; Matthias Briel; Alexandra D'Amario; Jos Kleijnen; Ana Marusic; Elizabeth Wager; Gerd Antes; Erik von Elm; Britta Lang; Edith Motschall; Viktoria Gloy; Guido Schwarzer; Doug Altman; Joerg J Meerpohl; Dirk Bassler
Journal:  Syst Rev       Date:  2013-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.